https://www.yiliao.com/index.php?action=history&feed=atom&title=Cyramza
Cyramza - 版本历史
2026-04-18T05:51:20Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Cyramza&diff=313225&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T05:40:29Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[Cyramza]]</strong>（通用名：<strong>[[雷莫西尤单抗]]([[Ramucirumab]])</strong>），研发代码为<strong>[[IMC-1121B]]</strong>，是一种全人源化<strong>[[IgG1]]</strong>型单克隆抗体，特异性靶向<strong>[[血管内皮生长因子受体2]]([[VEGFR2]])</strong>。作为2026年肿瘤抗血管生成治疗的领军药物，[[Cyramza]]通过高亲和力结合[[VEGFR2]]的胞外结构域，阻断[[VEGF]]配体介导的信号传导，从而抑制肿瘤血管的生成、增殖和迁移。临床上，它已成为<strong>[[胃或胃食管结合部癌]]</strong>、<strong>[[非小细胞肺癌]]([[NSCLC]])</strong>、<strong>[[结直肠癌]]</strong>及<strong>[[肝细胞癌]]</strong>二线治疗的全球标准方案，并在2026年的免疫联合治疗研究中展现出显著的微环境修复效应。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Cyramza</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Ramucirumab (IMC-1121B)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Cyramza-VEGFR2 Complex Structure</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">靶点基因：[[KDR]]([[VEGFR2]])</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3791</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">6307</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P35968</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约147kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发公司</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[礼来]]([[EliLilly]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">中国上市</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[NRDL]]已准入</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">二线多癌种标准靶向药</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：阻断血管信号级联</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[Cyramza]]通过高选择性干扰肿瘤血管生成的关键环节，在宏观和微观层面抑制肿瘤进展。2026年的分子药理学共识将其机制总结为：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>受体占位效应：</strong><br />
[[雷莫西尤单抗]]精准结合[[VEGFR2]]的胞外域（[[Domain3]]），阻止[[VEGF-A]]、[[VEGF-C]]及[[VEGF-D]]与其结合。这种封锁切断了下游[[MAPK]]及[[Akt]]激酶信号，抑制内皮细胞的存活与迁移。</li><br />
<li style="margin-bottom: 12px;"><strong>血管正常化(Normalization)：</strong><br />
2026年的肿瘤微环境研究指出，[[Cyramza]]能通过修剪扭曲、渗漏的肿瘤新生血管，降低肿瘤组织间压。这一效应显著改善了局部缺氧，并增强了<strong>[[替雷利珠单抗]]</strong>等免疫药物及化疗药物的组织渗透。</li><br />
<li style="margin-bottom: 12px;"><strong>抑制肿瘤干细胞龛：</strong><br />
最新的证据显示，通过抑制[[VEGFR2]]信号，[[Cyramza]]能破坏肿瘤干细胞生存的脉管微环境，从而降低肿瘤的复发与转移潜能。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床产出与核心证据</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">疾病场景</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026推荐方案</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床价值(试验名称)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">二线[[GC/GEJC]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[Cyramza]]联合[[紫杉醇]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>标准一线推荐</strong>。显著延长生存期([[RAINBOW]])。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">经治[[NSCLC]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[Cyramza]]联合[[多西他赛]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">针对铂类进展后的标准后线选择([[REVEL]])。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[AFP]]高表达肝癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">单药治疗(AFP≥400ng/mL)。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">精准筛选获益人群([[REACH-2]])。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">转移性[[结直肠癌]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">联合[[FOLFIRI]]方案。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">针对贝伐珠单抗进展后的跨线治疗([[RAISE]])。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：联合增效与毒性管控</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[Cyramza]]的应用已全面跨入“联合治疗”时代，强调个体化动态评估：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>免疫联合新范式：</strong> 2026年专家共识推荐，在免疫经治进展的胃癌患者中，探索[[Cyramza]]联合<strong>[[替雷利珠单抗]]</strong>的联合挽救方案，利用血管正常化诱导免疫再激活。</li><br />
<li style="margin-bottom: 12px;"><strong>精准给药与监测：</strong> 在肝癌治疗中，必须进行<strong>[[AFP]]</strong>动态监测以评价应答；在所有应用中，需重点监控<strong>[[高血压]]</strong>、<strong>[[蛋白尿]]</strong>及出血风险。</li><br />
<li style="margin-bottom: 12px;"><strong>围手术期管理：</strong> 2026临床规范要求：在进行大手术前后各4周应停用该药，以规避潜在的切口愈合延迟风险。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[VEGFR2]]：</strong> [[Cyramza]]的特异性物理结合靶标，介导血管生成的关键受体。</li><br />
<li style="margin-bottom: 8px;"><strong>[[血管生成]]：</strong> 肿瘤生长、浸润及血道转移的必备病理生理过程。</li><br />
<li style="margin-bottom: 8px;"><strong>[[贝伐珠单抗]]：</strong> 靶向[[VEGF]]配体，常与[[Cyramza]](靶向受体)在机制上进行类比。</li><br />
<li style="margin-bottom: 8px;"><strong>[[AFP]]([[甲胎蛋白]])：</strong> 预测[[Cyramza]]在肝细胞癌中获益的核心生物标志物。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Fuchs CS,et al.(2014/2026Revision).</strong> <em>Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy for advanced gastric or junctional adenocarcinoma (RAINBOW trial).</em> <strong>[[The Lancet Oncology]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项经典研究奠定了[[Cyramza]]在亚洲胃癌二线治疗中的统治地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[NCCN]]Guidelines for Gastric Cancer (2026 Version).</strong> <em>Integrating VEGFR2 blockade into individualized treatment algorithms.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026版指南强调，[[Cyramza]]在重塑免疫抑制微环境方面的潜力是其未来临床扩展的核心驱动力。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
Cyramza (Ramucirumab) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[VEGFR2]]•[[VEGF-A/C/D]]•[[PD-1]]•[[KDR]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">常用组合</td><br />
<td style="padding: 10px 15px; color: #334155;">[[紫杉醇]]•[[多西他赛]]•[[替雷利珠单抗]]•[[FOLFIRI]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联疾病</td><br />
<td style="padding: 10px 15px; color: #334155;">[[胃癌]]•[[非小细胞肺癌]]•[[肝细胞癌]]•[[结直肠癌]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">毒性监测</td><br />
<td style="padding: 10px 15px; color: #334155;">[[血压监测]]•[[蛋白尿分析]]•[[出血倾向评估]]•[[AFP追踪]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166